 |
 |
|
|
|
| Estradiol enantate |
 |
| White powder |
 |
| 4956-37-0 |
 |
It is a kind of estrogen, can promote and regulate the normal development of women's genitals and secondary. Can cause hyperplasia of mammary gland carcinoma development, but in larger doses, can inhibit pituitary prolactin release, and reduce the secretion of milk. Potent mammalian estrogenic hormone produced by the ovary.
|
 |
Synonyms: oestradiol 17-heptanoate
CAS: 4956-37-0
Molecular formula: C25H36O3
Molecular Weight: 384.55
Appearance: White powder
Packing: 1kg/Tin
2. Description:
Estradiol enanthate, or estradiol enantate, is a synthetic ester, specifically the 17-heptanoyl ester, of the natural estrogen, estradiol. Which are combination formulations of estradiol enanthate and dihydroxyprogesterone acetophenide, as a once-monthly injectable hormonal contraceptive in Spain and Latin America, and has been used as such since at least the mid-1960s.
Function and use: It is a kind of estrogen, can promote and regulate the normal development of women's genitals and secondary. Can cause hyperplasia of mammary gland carcinoma development, but in larger doses, can inhibit pituitary prolactin release, and reduce the secretion of milk. Potent mammalian estrogenic hormone produced by the ovary.
3.Application:
When estrogen is prescribed for a woman with a uterus, progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary. For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Short-term cyclic use for treatment of moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible.
Attempts to discontinue or taper medication should be made at 3- to 6-month intervals. The usual dosage range is 1 to 5 mg injected every 3 to 4 weeks.
For treatment of female hypoestrogenism due to hypogonadism 1.5 to 2 mg injected at monthly intervals.
|
|
|
|
|
|
